Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Huddinge – page 13

218 clinical trials in Huddinge, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Huddinge at a glance
218
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

218 trials in Huddinge

Open in trial search

Amyotrophic lateral sclerosis

Not recruiting

Study on the Effects of Triumeq (Abacavir Sulfate, Lamivudine, Dolutegravir Sodium) in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir Sulfate
  • Sponsor:Stichting TRICALS Foundation

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Porphyria non-acute

Not recruiting

Study on the Safety and Tolerability of Oral Dersimelagon for Patients with Erythropoietic Protoporphyria or X-Linked Protoporphyria

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate
  • Sponsor:Tanabe Pharma America Inc.

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma refractory

Not recruiting

Study of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neurodegenerative disorder

Not recruiting

Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Polycythaemia vera+10

Not recruiting

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Panobinostat
  • Sponsor:Novartis Pharma Services AG

Kidney transplant rejection

Not recruiting

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Huddinge

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure prevention and cardiovascular disease, including investigations into cholesterol metabolism and blood pressure management.

  • PCSK9 inhibitors and statins research
  • Heart failure prevention trials
  • Lipoprotein management studies

Comprehensive research focusing on reducing cardiovascular events and improving patient outcomes.

02 Oncology Studies

Groundbreaking research in blood cancers, including acute myeloid leukemia and multiple myeloma, with innovative therapeutic approaches.

  • Advanced breast cancer treatments
  • Leukemia therapy combinations
  • CAR T Cell therapy trials

Studies evaluating novel treatment combinations and targeted therapies for various cancer types.

03 Neurological Disorders

Clinical investigations focusing on Alzheimer's disease and amyotrophic lateral sclerosis, exploring innovative therapeutic approaches.

  • Cognitive impairment treatments
  • ALS survival studies
  • Inflammatory response research

Studies examining new therapeutic options for progressive neurological conditions.

04 Chronic Conditions

Research initiatives addressing chronic kidney disease, cystic fibrosis, and other long-term health conditions.

  • Kidney disease management
  • Diabetes treatment studies
  • Organ transplant research

Comprehensive studies aimed at improving quality of life for patients with chronic conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.